Vaccine composition against Chlamydiaceae infections
US-11229691-B2 · Jan 25, 2022 · US
Vaccine composition against Chlamydiaceae infections
US11865169B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11865169-B2 |
| Application number | US-202117552256-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 15, 2021 |
| Priority date | Jul 28, 2015 |
| Publication date | Jan 9, 2024 |
| Grant date | Jan 9, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of protecting against infections caused by Chlamydia bacteria selected from the group consisting of Chlamydia muridarum, Chlamydia pneumoniae, Chlamydia psitacci, Chlamydia abortus, Chlamydia felis, Chlamydia caviae, Chlamydia pecorum, Chlamydia suis and Chlamydia trachomatis , comprising: administering to a subject a composition comprising an immunogenic dose of an inactivated β-lactam-treated form of Chlamydia bacteria selected from the group consisting of Chlamydia muridarum, Chlamydia pneumoniae, Chlamydia psitacci, Chlamydia abortus, Chlamydia felis, Chlamydia caviae, Chlamydia pecorum, Chlamydia suis and Chlamydia trachomatis, wherein the inactivated β-lactam-treated form of Chlamydia bacteria has been previously inactivated by treating with a β-lactam. 2. The method of claim 1 , wherein the β-lactam is selected from the group consisting of amoxicillin, benzylpenicillin, phenoxymethylpenicillin, cloxacillin, cefadroxil, cefixime, imipenem, mecillinam, clavulanic acid, tazobactam, sulbactam, and cefixime in combination with imipenem. 3. The method of claim 2 , wherein said β-lactam is benzylpenicillin. 4. The method of claim 3 , wherein the Chlamydia bacteria is Chlamydia trachomatis. 5. The method of claim 1 , wherein the composition is administered in a repeated manner between 2 and 4 times over a period of 15 to 90 days. 6. The method of claim 5 , wherein one or more booster administrations are carried out between 1 and 10 years after the first administration. 7. The method of claim 2 , wherein the composition is administered in a repeated manner between 2 and 4 times over a period of 15 to 90 days. 8. The method of claim 7 , wherein one or more booster administrations are carried out between 1 and 10 years after the first administration. 9. The method of claim 3 , wherein the composition is administered in a repeated manner between 2 and 4 times over a period of 15 to 90 days. 10. The method of claim 9 , wherein one or more booster administrations are carried out between 1 and 10 years after the first administration. 11. The method of claim 1 , wherein the Chlamydia bacteria is Chlamydia trachomatis. 12. The method of claim 2 , wherein the Chlamydia bacteria is Chlamydia trachomatis.
Assignees
Inventors
Classifications
- A61K39/118Primary
Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci · CPC title
Antibacterial agents · CPC title
Chlamydia · CPC title
inactivated (killed) · CPC title
Infectious diseases, e.g. generalised sepsis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11865169B2 cover?
- The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.
- Who is the assignee on this patent?
- Centre Nat Rech Scient, Univ Paris Diderot Paris 7, Inst Nat Sante Rech Med
- What technology area does this patent fall under?
- Primary CPC classification A61K39/118. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).